Oakwood Laboratories, L.L.C. and Santen Pharmaceutical Co., Ltd., of Osaka, Japan, have entered into an agreement for the licensing of Oakwood’s drug delivery technology for use with Santen’s steroidal product (DE-102) to treat Diabetic Macular Edema (DME). Under the agreement, Oakwood will provide formulation and dosage form development, and manufacturing of clinical and commercial scale supplies of DE-102, using Oakwood’s Chroniject microsphere-based sustained release injectable technology. ...